Status:
COMPLETED
ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer
Lead Sponsor:
Mayo Clinic
Conditions:
Pancreas Cancer
Pancreas Cyst
Eligibility:
All Genders
17+ years
Phase:
NA
Brief Summary
Researchers have developed a new test to measure a protein QSOX1 that is found to be elevated in subjects with pancreas cancer. Researchers are looking to use this test to compare subjects with pancre...
Eligibility Criteria
Inclusion
- Adult patients with biopsy-proven adenocarcinoma prior to receiving any therapy such as surgery, radiation or chemotherapy.
- Patients without pancreas cancer.
- Adult patients with benign pancreas disorders such as pancreatitis with imaging within 12 months (CT, MRI, EUS) documenting no cancer.
- Healthy adults with blood specimens in an existing biobank.
- Patients with pancreatic cystic lesions.
- Adult patients undergoing clinically indicated EUS-guided FNA biopsy of pancreatic cystic lesions.
Exclusion
- Prior treatment for pancreas cancer.
- Unable or unwilling to give consent.
Key Trial Info
Start Date :
August 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04064034
Start Date
August 1 2019
End Date
October 31 2020
Last Update
December 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259